Background. Streptococcus pneumoniae is a common cause of otitis media (OM) in children; mastoiditis remains an important complication of OM. Limited data are available on the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal otitis.
world where PCV7 was introduced [10] [11] [12] . Early data suggest that 13-valent pneumococcal conjugate vaccine (PCV13; which includes the PCV7 serotypes along with serotypes 1, 3, 5, 6A, 7F, and 19A and was introduced in the United States in 2010) is associated with reduced nasopharyngeal (NP) carriage of PCV13 serotypes in children with OM [13, 14] , decreased isolation of PCV13 serotypes from children undergoing tympanocentesis or from spontaneous ear drainage [15] , and decreased isolation of S. pneumoniae from middle ear cultures of children undergoing pressure equalization (PE) tube placement [16] .
The purpose of this study was to describe the pneumococcal serotypes and antibiotic susceptibilities of pneumococcal isolates recovered from middle ear or mastoid cultures obtained during clinical management of children being seen at 8 children's hospitals in the United States from 1 January 2011 through 31 December 2013. Prior receipt of PCV7 and/or PCV13 was also captured.
METHODS
Investigators from 8 children's hospitals prospectively collected pneumococcal isolates from middle ear cultures (spontaneous drainage, PE tube placement, myringotomy) or mastoid surgical cultures. The study was approved with informed consent being waived by the institutional review boards of each participating hospital. Selected demographic and clinical information, antibiotic susceptibilities from the clinical laboratory of the respective children's hospital, and date and type of PCV administered prior to the infection for which the culture was obtained were entered onto a standard case report form. A PCV13 dose was counted if administered 2 or more weeks before the date that the S. pneumoniae was isolated from the middle ear or mastoid culture.
The patient database was maintained in a central office (Texas Children's Hospital and Baylor College of Medicine, Houston, Texas). Pneumococcal isolates were identified, and antimicrobial susceptibility testing was performed using standard methods in the microbiology laboratories of each hospital. The isolates were sent to the Infectious Disease Research Laboratory at Texas Children's Hospital for serotyping. Antibiotic susceptibility categories were as defined by the 2014 Clinical and Laboratory Standards Institute [17] . Pneumococcal isolates were serotyped using commercially available antisera (Statens Seruminstitut, Copenhagen, Denmark; Cedarlane Laboratories USA, Burlington, North Carolina) [18] . Serotype 6C was considered a PCV13-related serotype [19] .
Dichotomous variables were analyzed using the χ 2 or χ 2 test for trend. True Epistat (Epistat Σ Services, Richardson, Texas) was the statistical program used.
RESULTS
The total numbers of isolates from middle ear or mastoid cultures each year were 154 in 2011, 118 in 2012, and 120 in 2013.
The total number of isolates from only mastoid cultures was 35 (19 in 2011, 7 in 2012, and 9 in 2013). The median age and age ranges for each study year were very similar (Table 1) . Overall, 253 patients were aged <2 years, 103 were ≥2 years and <6 years, and 36 were ≥6 years. The next most common PCV13 serotype isolated was serotype 3: 8 in 2011, 9 in 2012, and 12 in 2013. This increase in number of serotype 3 isolates recovered was not a significant trend with respect to the proportion of isolates being serotype 3 each year (P = .14). Three children had received 3 doses and 5 had received 4 doses of PCV13 prior to culture. Twenty-one children had received <3 PCV13 doses prior to culture. Thus, 72% of children received <3 doses of PCV13 prior to culture and almost half had not received any dose of PCV13. Among these children, 6 serotype 3 isolates were recovered from mastoid cultures; 4 of these 6 patients had received <3 doses of PCV13.
Serotypes 19F and 7F accounted for 15 isolates and 1 isolate for the combined years, respectively. Nine of the 16 children with these serotypes had not received any PCV13 doses. Of the 15 children with 19F isolates, 4 had received 3 or 4 doses of PCV13 and 7 had received 3 or 4 doses of PCV7. The child with the 7F isolate had not received any doses of PCV13.
In 2011, 75 isolates were non-PCV13 and related serotypes; in 2012, 69 isolates were non-PCV13 and related serotypes; and in 2013, 84 isolates were non-PCV13 and related serotypes. The most common non-PCV13 serotypes for the combined years were serotype 35B (n = 37), serotype 21 (n = 20), serotype 23B (n = 20), serotype 15B (n = 18), serotype 11 (n = 17), serotype 23A (n = 14), serotype 15A (n = 14), serotype 15C (n = 14), serotype 16 (n = 11), and serotype 31 (n = 10). Table 3 summarizes the number of isolates per serotype for mastoiditis cases each year. Serotype 19A was the most common serotype overall but declined over the years from 7 isolates in 2011 to 1 isolate in 2013. Serotype 3 was the second most common serotype without evidence that a decrease in numbers occurred over the 3-year study period. Although serotype 35B was the most common non-PCV13 serotype for all isolates, only 1 of 37 such isolates was recovered from mastoid cultures. In contrast, 3 of 9 serotype 22F isolates were from mastoid cultures.
Antibiotic Susceptibilities
The distribution of isolates based on minimal inhibitory concentrations (MICs) for penicillin is shown in Figure 1 Table 4 . Over the 3 years, the proportion of isolates susceptible to clindamycin increased (P = .0004). Serotype 19A isolates were more likely to be resistant to these 3 antibiotics than non-serotype 19A isolates (Table 5) .
DISCUSSION
Since the introduction of PCV13 for routine use in infants and young children, the incidence of invasive pneumococcal disease (IPD) in children has decreased in the United States and other countries in which PCV13 has replaced routine administration of PCV7 [18, [20] [21] [22] [23] . Decreases in IPD caused by serotypes 19A, 7F, and 3 have been demonstrated [21] . Fewer studies have focused on the impact of PCV13 on the frequency of OM due to S. pneumoniae. Several investigators have reported a decline in nasal colonization by PCV13-serotype pneumococci in children following the introduction of PCV13 into national immunization programs [13, [24] [25] [26] [27] . Investigators in France reported that children presenting with AOM were significantly less likely to carry PCV13 serotypes (19A, 7F, 6C) in the nasopharynx if they had received at least 1 dose of PCV13 compared with children who had received PCV7 only [13] . Serotypes 15A and 11A were the most common non-PCV13 serotypes isolated in this study, consistent with the findings of other NP colonization studies in which the most common non-PCV13 serotypes isolated included 15A, 15B/C, 6C, 11A, 35B, 23B, 21, 23A, and 16F [13, [24] [25] [26] [27] .
The impact of PCV13 on the frequency and etiologies of OM in children has been more difficult to assess since tympanocentesis for AOM is not routinely performed in clinical practice. In a preliminary report of an ongoing study that enrolled 60 children who had completed the 3-dose infant PCV13 series between October 2010 and September 2011, Pichichero et al [14] found that of 15 children who had tympanocentesis for AOM, only 1 child had S. pneumoniae (serotype 11) isolated from a middle ear fluid culture. In contrast, of 58 children enrolled in a separate but similarly designed study from October 2007 to September 2009, 7 of 15 pneumococcal isolates from children with AOM undergoing tympanocentesis were serotype 19A. Zhao et al [16] cultured middle ear fluids of 118 children undergoing PE tube placement between August 2012 and April 2013 for recurrent OM (n = 112), middle ear effusion (n = 6), and conductive hearing loss. Sixty-six patients had received PCV13 only and 25 had received some combination of PCV7 and PCV13. Only 1 S. pneumoniae isolate (serotype 16) was recovered from an 8-year-old patient. Utilizing the claims data from a large US managed healthcare plan, Marom et al [28] estimated that there was a significant drop in the observed OM visits in 2010 and 2011 and that they were lower than the projected number of visits for OM based on the trend for claims in [2005] [2006] [2007] [2008] [2009] . The decline in visits for children aged <2 years coincided with the introduction of PCV13. In the most comprehensive study to date on incidence of pneumococcal OM, Ben-Shimol et al [15] noted a marked reduction of OM caused by PCV13 serotypes in southern Israel following the sequential introduction of PCV7 and then PCV13 for routine use.
In our multicenter surveillance study, pneumococcal OM and mastoiditis isolates were obtained from a variety of sources including spontaneous otorrhea, middle ear fluid obtained at the time of PE tube placement, myringotomy cultures, and mastoid cultures, starting in January 2011, about 6 months after PCV13 was being widely used in the United States. Thus, our surveillance of pneumococcal isolates represents a combination of isolates from children with acute, recurrent, or chronic otitis media. There was a decrease in the total number of isolates in 2012 (n = 118) compared with 2011 (n = 154); however, in 2013 (n = 120), the number of isolates remained stable. Importantly, 
Abbreviations: I, intermediate; R, resistant; S, susceptible. the number and proportion of isolates that were PCV13 serotypes decreased substantially over the course of the study, especially for serotype 19A and the 6A-related serotype, 6C. Although almost 50% of the children from whom a serotype 19A isolate was recovered had received 3 or 4 doses of PCV13 prior to the episode, the number of serotype 19A isolates decreased by 75% when results for 2011 were compared with those for 2013. There was no decline in serotype 3 isolates, which has been noted in trials of other pneumococcal conjugate vaccines that contain serotype 3 for preventing AOM caused by S. pneumoniae [29] . However, in our study, almost half of the children from whom a serotype 3 strain was isolated had not received any doses of PCV13. Furthermore, in the study from southern Israel, OM caused by serotype 3 declined 51% following the introduction of PCV7 and then PCV13 compared with the prevaccine period [15] . In general, the non-PCV13 serotypes noted to be commonly carried in the nasopharynx in the post-PCV13 studies described previously are the most common serotypes among the OM isolates in our surveillance study, with serotype 35B and serogroup 15 (A/B/C combined) isolates predominating. Ben-Shimol et al [15] reported similar findings. After PCV7 became widely used, mastoiditis caused by serotype 19A was increasingly recognized and became the most common pneumococcal serotype associated with mastoiditis in areas around the world [8, 30] . Others reported an increase in the frequency or severity of acute mastoiditis several years after PCV7 was introduced. This is consistent with serotype 19A being associated with a greater likelihood of causing complicated acute mastoiditis than perhaps other pneumococcal serotypes thought to be, in part, related to increased rates of antibiotic resistance in serotype 19A isolates [9, 31] . Marom et al [28] found that rates of mastoiditis insurance claims decreased significantly during 2009-2011 compared with 2001-2008 when the rates were stable. We noted that the number of pneumococcal isolates associated with mastoiditis declined in 2012 and 2013 compared with 2011, especially for serotype 19A, of which only 1 isolate was found in 2013. Serotype 3 was the second most common serotype recovered from children over the 3-year study; however, 4 of the 6 children with serotype 3 mastoiditis had not received any PCV13 doses. In 2013, the last year of the study, serotype 3 was the most common pneumococcal serotype isolated from children with mastoiditis, accounting for 4 of 9 isolates.
Over the 3-year surveillance period, the proportion of isolates with high-level penicillin resistance decreased significantly, mainly as a consequence of the reduction in the number of serotype 19A isolates, which were also much more likely to be multidrug resistant than the non-serotype 19A isolates. In 2013 overall, 90% of isolates had penicillin MIC ≤ 2 µg/mL. Our isolates were a combination of isolates obtained from children with acute or chronic OM and likely overestimated the proportion of pneumococcal isolates causing AOM that are resistant to penicillin. If serotype 19A isolates continue to decline, decreasing levels of penicillin resistance among OM isolates would be expected, perhaps to the point that the lower standard dose of amoxicillin (40-45 mg/kg/day) rather than the high dose of amoxicillin (80-90 mg/kg/day) could be considered the firstline treatment for AOM [32, 33] .
Our study has a number of limitations. The isolates were collected from children for clinical indications from a variety of sources such as draining ears, surgical cultures from PE tube placement, and mastoid cultures. Thus, the isolates are representative of the spectrum of OM and not AOM specifically. Antibiotic susceptibilities were measured by the clinical microbiology laboratory of each children's hospital using techniques that were not uniform, as would be the case if susceptibilities were determined in a central laboratory. Our data are not population based, so rates of pneumococcal OM episodes cannot be determined. Finally, our isolates were obtained from children who were seen at the participating children's hospitals and may not be representative of children in the general population. However, a strength of our study is the multicenter design.
In summary, over a 3-year period starting approximately 6 months after the widespread use of PCV13 in the United States, we found a decrease in the number of pneumococcal isolates from cultures taken from children with OM or mastoiditis for clinical indications. This decline was largely related to decreases in serotype 19A, and the proportion of isolates that represented serotypes in PCV13 decreased significantly over the study period. In association with the decline in serotype 19A isolates, the percentage of isolates with high-level penicillin resistance also decreased significantly. Continued decreases in the frequency of pneumococcal OM along with declining rates of penicillin resistance may warrant consideration of modifying recommendations for amoxicillin dosing for treatment of AOM. Additional studies will help clarify the full impact of PCV13 on the frequency and management of AOM in children.
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